Human variability in xenobiotic metabolism and pathway-related uncertainty factors for chemical risk assessment: a review
Human variability in xenobiotic metabolism and pathway-related uncertainty factors for chemical risk assessment: a review
This review provides an account of recent developments arising from a database that defined human variability in phase I metabolism (CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, hydrolysis, alcohol dehydrogenase), phase II metabolism (N-acetyltransferases, glucuronidation, glycine conjugation, sulphation) and renal excretion. This database was used to derive pathway-related uncertainty factors for chemical risk assessment that allow for human variability in toxicokinetics. Probe substrates for each pathway of elimination were selected on the basis that oral absorption was >95% and that the metabolic route was the primary route of elimination of the compound (60–100% of a dose). Intravenous data were used for compounds for which absorption was variable. Human variability in kinetics was quantified for each compound from published pharmacokinetic studies (after oral and intravenous dosing) in healthy adults and other subgroups of the population using parameters relating to chronic exposure (metabolic and total clearances, area under the plasma concentration–time curve (AUC) and acute exposure (Cmax) (data not presented here). The pathway-related uncertainty factors were calculated to cover 95%, 97.5% and 99% of the population of healthy adults and of each subgroup.
Pathway-related uncertainty factors allow metabolism data to be incorporated into the derivation of health-based guidance values. They constitute an intermediate approach between the general kinetic default factors (3.16) and a chemical-specific adjustment factor. Applications of pathway-related uncertainty factors for chemical risk assessment and future refinements of the approach are discussed. A knowledge-based framework to predict human variability in kinetics for xenobiotics showing a threshold dose below which toxic effects are not observed, is proposed to move away from default assumptions.
human variability, pharmacokinetics, metabolism, pathway-related uncertainty factors, chemical risk assessment
203-216
Dorne, J.L.
b8c3f762-57b5-4082-a290-a7ca22efaeb0
Walton, K.
024c9ff2-0a40-4fda-a213-db73d9971871
Renwick, A.G.
596705ab-5418-4e02-9ad7-c4309326df46
2005
Dorne, J.L.
b8c3f762-57b5-4082-a290-a7ca22efaeb0
Walton, K.
024c9ff2-0a40-4fda-a213-db73d9971871
Renwick, A.G.
596705ab-5418-4e02-9ad7-c4309326df46
Dorne, J.L., Walton, K. and Renwick, A.G.
(2005)
Human variability in xenobiotic metabolism and pathway-related uncertainty factors for chemical risk assessment: a review.
Food and Chemical Toxicology, 43 (2), .
(doi:10.1016/j.fct.2004.05.011).
Abstract
This review provides an account of recent developments arising from a database that defined human variability in phase I metabolism (CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, hydrolysis, alcohol dehydrogenase), phase II metabolism (N-acetyltransferases, glucuronidation, glycine conjugation, sulphation) and renal excretion. This database was used to derive pathway-related uncertainty factors for chemical risk assessment that allow for human variability in toxicokinetics. Probe substrates for each pathway of elimination were selected on the basis that oral absorption was >95% and that the metabolic route was the primary route of elimination of the compound (60–100% of a dose). Intravenous data were used for compounds for which absorption was variable. Human variability in kinetics was quantified for each compound from published pharmacokinetic studies (after oral and intravenous dosing) in healthy adults and other subgroups of the population using parameters relating to chronic exposure (metabolic and total clearances, area under the plasma concentration–time curve (AUC) and acute exposure (Cmax) (data not presented here). The pathway-related uncertainty factors were calculated to cover 95%, 97.5% and 99% of the population of healthy adults and of each subgroup.
Pathway-related uncertainty factors allow metabolism data to be incorporated into the derivation of health-based guidance values. They constitute an intermediate approach between the general kinetic default factors (3.16) and a chemical-specific adjustment factor. Applications of pathway-related uncertainty factors for chemical risk assessment and future refinements of the approach are discussed. A knowledge-based framework to predict human variability in kinetics for xenobiotics showing a threshold dose below which toxic effects are not observed, is proposed to move away from default assumptions.
This record has no associated files available for download.
More information
Published date: 2005
Keywords:
human variability, pharmacokinetics, metabolism, pathway-related uncertainty factors, chemical risk assessment
Identifiers
Local EPrints ID: 27034
URI: http://eprints.soton.ac.uk/id/eprint/27034
ISSN: 0278-6915
PURE UUID: 2b7402e9-80f2-435e-ada3-6bf7b05c51a5
Catalogue record
Date deposited: 25 Apr 2006
Last modified: 15 Mar 2024 07:15
Export record
Altmetrics
Contributors
Author:
J.L. Dorne
Author:
K. Walton
Author:
A.G. Renwick
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics